🎀 GYN Oncology — 2026-W37

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Large multi-center registry analysis (SURROC-CON, n>3000) in recurrent epithelial ovarian cancer, published in Int J Gynecol Cancer, evaluating outcomes after secondary cytoreductive surgery versus chemotherapy alone. Supports secondary cytoreduction (with complete clearance) as associated with substantially better survival, reinforcing patient selection criteria including BRCA status for surgical candidacy in recurrent disease.

Retrospective real-world cohort study (ESME database) in platinum-resistant high-grade ovarian carcinoma, published in Int J Gynecol Cancer, comparing chemotherapy regimens with/without bevacizumab. Suggests paclitaxel-based regimens may outperform gemcitabine or PLD, informing chemotherapy backbone choice in this setting but based on non-randomized data with modest sample size.

Narrative review summarizing the molecular and clinical landscape of NSMP endometrial cancer, published in Gynecologic Oncology. Discusses current and emerging therapies (endocrine, targeted, immunotherapy, ADCs) and highlights need for molecular stratification in future trials, informing treatment approach for this common subtype.

Bayesian segregation analysis study in JCO Precision Oncology estimating age-specific ovarian cancer risk in PALB2 germline pathogenic variant carriers. Provides risk data relevant to genetic counseling and screening decisions rather than therapy selection.

Narrative review on antibody-drug conjugates and emerging systemic strategies in platinum-resistant ovarian cancer, published in Therapeutic Advances in Medical Oncology. Summarizes current and investigational treatment approaches including ADCs, glucocorticoid receptor antagonists, and immune-chemotherapy combinations, informing treatment sequencing decisions in this setting.

Retrospective single-institution cohort study of endometrial cancer patients receiving chemotherapy, published in Gynecologic Oncology. Finds a high rate of venous thromboembolism, especially in advanced-stage disease, highlighting an opportunity for better VTE risk assessment in this population.

AJCC staging protocol update (version 9) for vulvar carcinoma, published in CA Cancer J Clin, aligning with 2021 FIGO staging changes. Revises T/N/M subcategories, which may affect stage-based treatment classification though it is primarily a staging rather than treatment guideline.

Post hoc patient-reported outcomes analysis from the phase 3 innovaTV 301 trial comparing tisotumab vedotin to chemotherapy in recurrent/metastatic cervical cancer, published in Int J Gynecol Cancer. Provides quality-of-life data supporting the drug's tolerability profile alongside its previously shown survival benefit.

Prospective multi-institution Japanese registry/cohort study evaluating pembrolizumab in MSI-high endometrial cancer, published in Journal of Gynecologic Oncology. Reports response and survival outcomes along with exploratory biomarkers (MLH1 methylation, obesity), offering supportive real-world data but not changing established practice.